Filing Flows › Pharma-Bio Serv (PBSV) › Q2 FY26 › vs Q2 FY25
Pharma-Bio Serv (PBSV) Q2 FY26 vs Q2 FY25 (year over year)
Pharma-Bio Serv's revenue rose $286K (+12%) from $2.4M in Q2 FY25 to $2.7M in Q2 FY26. Gross margin 33.4% against 33.9% (-0.5 pts).
Pharma-Bio Serv, Q2 FY26: revenue $2.7M (+12% year over year), operating margin 5.4%, net earnings $233K, operating cash flow −$365K. The chart draws each line against Q2 FY25, the increases inside each band.
Margins
| Q2 FY26 | Q2 FY25 | Change | |
|---|---|---|---|
| Gross margin | 33.4% | 33.9% | -0.5 pts |
| Operating margin | 5.4% | -4.1% | +9.4 pts |
| Net margin | 8.6% | 3.9% | +4.7 pts |
Every line
| Line | Q2 FY26 | Q2 FY25 | Change | % |
|---|---|---|---|---|
| Revenue | $2.7M | $2.4M | $286K | +12% |
| Gross profit | $902K | $819K | $83K | +10% |
| Cost of revenue | $1.8M | $1.6M | $203K | +13% |
| Other income, net | $95K | $199K | −$105K | -52% |
| Operating profit | $145K | −$98K | $243K | — |
| Operating expenses | $757K | $917K | −$160K | -17% |
| Pre-tax earnings | $239K | $101K | $138K | +137% |
| Net earnings | $233K | $95K | $138K | +144% |
| Income tax | $6K | $6K | $1K | +16% |
| Operating cash sources | $621K | $426K | $195K | +46% |
| Depreciation & amortization | $14K | $19K | −$5K | -28% |
| Share-based compensation | $9K | $10K | −$1K | -14% |
| Cash used in operations | $365K | $302K | $64K | +21% |
| Working capital & other | $621K | $426K | $195K | +46% |
Questions
How much did Pharma-Bio Serv's revenue grow year over year in Q2 FY26?
Pharma-Bio Serv's revenue rose $286K (+12%) from $2.4M in Q2 FY25 to $2.7M in Q2 FY26. Gross margin 33.4% against 33.9% (-0.5 pts).